<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2530-5115</journal-id>
<journal-title><![CDATA[Hospital a Domicilio]]></journal-title>
<abbrev-journal-title><![CDATA[Hosp. domic.]]></abbrev-journal-title>
<issn>2530-5115</issn>
<publisher>
<publisher-name><![CDATA[Centro Internacional Virtual de Investigación en Nutrición (CIVIN)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2530-51152021000200005</article-id>
<article-id pub-id-type="doi">10.22585/hospdomic.v5i2.130</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Abordaje de la hiperpotasemia: desde urgencias a la unidad de hospitalización domicilio]]></article-title>
<article-title xml:lang="en"><![CDATA[Management of hyperkalemia: from the emergency department to the home hospitalization unit]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuentes Merlos]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garrido Navarro]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Bas Valero]]></surname>
<given-names><![CDATA[Rafael]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de San Juan de Alicante Servicio de Urgencias Hospitalarias ]]></institution>
<addr-line><![CDATA[Sant Joan d'Alacant ]]></addr-line>
<country>Espan&#771;a</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario de San Juan de Alicante Unidad de Hospitalizacio&#769;n a Domicilio ]]></institution>
<addr-line><![CDATA[Sant Joan d'Alacant ]]></addr-line>
<country>Espan&#771;a</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>5</volume>
<numero>2</numero>
<fpage>125</fpage>
<lpage>130</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2530-51152021000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2530-51152021000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2530-51152021000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La hiperpotasemia es una anomalía eléctrica común que puede empeorar arritmias cardíacas y aumentar significativamente la mortalidad. El envejecimiento progresivo de la población sumado a la mayor incidencia de entidades como la diabetes mellitus (DM), enfermedades cardiovasculares (ECV) o enfermedad renal crónica (ECV) así como el creciente uso de inhibidores del sistema renina angiotensina aldosterona (RAASi) ha provocado que sea un problema frecuente al que tenga que enfrentarse el clínico en su día a día. Presentamos un caso de un paciente ingresado a cargo de la Unidad de Hospitalizacio&#769;n a Domicilio de San Juan de Alicante que presentaba un cuadro de inicio súbito y clínica inespecífica debido a una hiperpotasemia grave. Tras estabilización previa en el servicio de urgencias, se realizó&#769; una combinación de tratamiento con fármacos RAASi, diuréticos de asa y resinas de intercambio catiónico (patiromero) presentando una mejoría de la sintomatología y control de la potasemia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Hyperkalemia is a common electrical abnormality that can worsen cardiac arrhythmias and significantly increase mortality. The progressive aging of the population added to the higher incidence of entities such as diabetes mellitus (DM), cardiovascular diseases (CVD) or chronic kidney disease (CVD) as well as the increasing use of renin angiotensin aldosterone system inhibitors (RAASi) has caused make it a frequent problem that clinicians have to face in their day-to-day life. We present a case of a patient admitted to the San Juan de Alicante Home Hospitalization Unit who presented a sudden onset and nonspecific clinical picture due to severe hyperkalemia. After prior stabilization in the emergency department, a combination of treatment with RAASi drugs, loop diuretics and cation exchange resins (patiromer) was performed, presenting an improvement in symptoms and control of potassium levels.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hiperpotasemia]]></kwd>
<kwd lng="es"><![CDATA[Terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Sistema Renina-Angiotensina]]></kwd>
<kwd lng="en"><![CDATA[Hyperkalemia]]></kwd>
<kwd lng="en"><![CDATA[Therapeutics]]></kwd>
<kwd lng="en"><![CDATA[Renin-Angiotensin System]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rafique]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chouihed]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mebazaa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Frank Peacock]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current treatment and unmet needs of hyperkalaemia in the emergency department]]></article-title>
<source><![CDATA[Eur Heart J Suppl]]></source>
<year>2019</year>
<volume>21</volume>
<numero>^sSuppl A</numero>
<issue>^sSuppl A</issue>
<supplement>Suppl A</supplement>
<page-range>A12-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovesdy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updates in hyperkalemia: Outcomes and therapeutic strategies]]></article-title>
<source><![CDATA[Rev Endocr Metab Disord]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kalantar-Zadeh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Turban]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Kovesdy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race]]></article-title>
<source><![CDATA[Nephron Clin Pract]]></source>
<year>2012</year>
<volume>120</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>c8-16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rossignol]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Legrand]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kosiborod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hollenberg]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Peacock]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Emmett]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emergency management of severe hyperkalemia Guideline for best practice and opportunities for the future]]></article-title>
<source><![CDATA[Pharmacol Res]]></source>
<year>2016</year>
<volume>113</volume>
<numero>A</numero>
<issue>A</issue>
<page-range>585-91</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Truhlár]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Deakin]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Soar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Khalifa]]></surname>
<given-names><![CDATA[GEA]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bierens]]></surname>
<given-names><![CDATA[JJLM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Resuscitation Council Guidelines for Resuscitation 2015: Section 4 - Cardiac arrest in special circumstances]]></article-title>
<source><![CDATA[Resuscitation]]></source>
<year>2015</year>
<volume>95</volume>
<page-range>148-201</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovesdy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Hyperkalemia: An Update for the Internist]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2015</year>
<volume>128</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1281-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovesdy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hyperkalaemia in chronic kidney disease]]></article-title>
<source><![CDATA[Nat Rev Nephrol]]></source>
<year>2014</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>653-62</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez-Navascués]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Vega]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bloqueo del sistema renina-angiotensina-aldosterona en hipertensión arterial, diabetes y nefropatía]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2008</year>
<numero>^s8(E)</numero>
<issue>^s8(E)</issue>
<supplement>8(E)</supplement>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Garza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>314</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-61</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Bushinsky]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Mayo]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Garza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stasiv]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>211-21</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
